1
|
Torikai M, Higuchi H, Yamamoto N, Ishikawa D, Fujita H, Taguchi K, Sakai F, Soejima K, Nakashima T. A novel monoclonal antibody cross-reactive with both human and mouse α9 integrin useful for therapy against rheumatoid arthritis. J Biochem 2021; 168:231-241. [PMID: 32271918 DOI: 10.1093/jb/mvaa040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2019] [Accepted: 03/28/2020] [Indexed: 11/14/2022] Open
Abstract
This study introduces a novel monoclonal anti-α9 integrin antibody (MA9-413) with human variable regions, isolated by phage display technology. MA9-413 specifically binds to both human and mouse α9 integrin by recognizing a conserved loop region designated as L1 (amino acids 104-122 of human α9 integrin). MA9-413 inhibits human and mouse α9 integrin-dependent cell adhesion to ligands and suppresses synovial inflammation and osteoclast activation in a mouse model of arthritis. This is the first monoclonal anti-α9 integrin antibody that can react with and functionally inhibit both human and mouse α9 integrin. MA9-413 allows data acquisition both in animal and human pharmacological studies without resorting to surrogate antibodies. Since MA9-413 showed certain therapeutic effects in the mouse arthritis model, it can be considered as a useful therapy against rheumatoid arthritis and other α9 integrin-associated diseases.
Collapse
Affiliation(s)
- Masaharu Torikai
- Research & Development Division, KM Biologics Co., Ltd, 1314-1 Kyokushi-Kawabe, Kikuchi, Kumamoto 869-1298, Japan
| | - Hirofumi Higuchi
- Research & Development Division, KM Biologics Co., Ltd, 1314-1 Kyokushi-Kawabe, Kikuchi, Kumamoto 869-1298, Japan
| | | | - Daisuke Ishikawa
- Research & Development Division, KM Biologics Co., Ltd, 1314-1 Kyokushi-Kawabe, Kikuchi, Kumamoto 869-1298, Japan
| | - Hirotada Fujita
- Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan
| | - Katsunari Taguchi
- Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan
| | - Fumihiko Sakai
- EVEC Inc., 6 Odori Nishi, Chuo-ku, Sapporo 060-0042, Japan
| | - Kenji Soejima
- Research & Development Division, KM Biologics Co., Ltd, 1314-1 Kyokushi-Kawabe, Kikuchi, Kumamoto 869-1298, Japan
| | - Toshihiro Nakashima
- The Chemo-Sero-Therapeutic Research Institute (Kaketsuken), 4-7 Hanabatacho, Chuo-ku, Kumamoto 860-0806, Japan
| |
Collapse
|